Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2017-07-17

Clinical Trial Update: Study of Panobinostat in Patients With Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 trial of panobinostat in patients with neuroendocrine tumors was terminated; results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Panobinostat (Panobinostat)

Snippet

Sponsor: University of Wisconsin, Madison | Conditions: Neuroendocrine Tumors | Phase 2 | Status: TERMINATED | Results posted: 2017-07-17